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Background: The introduction of the Enhanced Recovery After Surgery (ERAS) protocol after pan-
creaticoduodenectomy (PD) has led to a reduction in hospital stay (LOS) without compromising surgical
outcome. The primary endpoint of this study is to evaluate the adherence to postoperative targets of the
ERAS protocol, and to describe short-term surgical outcomes. The secondary endpoints are 30-day
readmission rate, reoperation rate and mortality.
Materials and methods: This single centre retrospective analysis reviews all data of patients who un-
derwent a PD in our tertiary referral hospital between August 2016 and December 2019. A total of 170
patients were operated of whom 154 patients were enrolled in the ERAS protocol. As per ERAS protocol,
epidural analgesia was stopped on postoperative day (POD) 2, nasogastric tube (NGT) removed on POD3,
regular food tolerated by POD5. Drains were removed on POD2 and POD3, the soft drain along the
pancreatic anastomosis between POD3-10.
Results: Epidural analgesia was removed on POD2 in 26 patients (17.7%), NGT removed on POD3 in 74
patients (49.0%), regular food tolerated by POD5 in 52 patients (34.9%). The lateral drain was removed in
81 patients (52.9%) on POD2, the medial drain in 39 patients (26.2%) on POD3, the soft drain in 95 pa-
tients (61.7%) between POD3 and 10. Nine patients (5.8%) had post-pancreatectomy haemorrhage (PPH),
14 (9.1%) postoperative pancreatic fistula grade B or C (POPF), 5 (3.3%) bile leakage, and 44 (28.6%)
delayed gastric emptying (DGE). The 30-day readmission rate was 8.4%, reoperation rate 10.4%, and the
in-hospital mortality 1.3%.
Conclusions: The adherence to targets of the ERAS protocol was found to be rather low. Biliary leakage,
POPF, DGE, and PPH all led to an adapted ERAS protocol with prolonged LOS. Most complications were
detected along the ERAS pathway, indicating that also patients at high risk for complications can be
safely included in the ERAS protocol.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreaticoduodenectomy (PD) is a complex surgical procedure
with significant morbidity and mortality. The Enhanced Recovery
After Surgery (ERAS) protocol is a formalised perioperative care
approach that suggest guidelines for the perioperative manage-
ment of PD. This protocol's main purpose is to optimise patients'
hospital course over the entire range of surgical care to reduce the
length of stay (LOS) [1e3]. Generalised concepts in the ERAScom (A.-S. Hufkens), stijn.
arvalho@uzgent.be (L. Abreu
ander), Frederik.Berrevoet@
vier Ltd on behalf of Surgical Assopathways focus on reducing surgical stress, narcotic-sparing pain
control, early ambulation, and promoting early oral diet [3e5].
Previous studies have explored the feasibility and efficacy of the
ERAS protocol in PD in terms of LOS, postoperative morbidity, and
readmission rate. These studies show that the ERAS protocol was
not inferior to the conventional postoperative program with
regards to overall operation-related morbidity rates. There was no
significant increase in serious adverse events nor in the read-
mission rates, indicating that patients were not discharged before
medically ready [3,6,7]. The implementation of ERAS protocols
seems to accelerate perioperative recovery and quality-of-life,
thereby reducing the LOS without compromising surgical
outcome [6e10], and might lead to significant reduction of in-
hospital costs [6,7,10]. The perioperative ERAS pathway has
shown to be a safe and a worthy replacement for conventionalciates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Change of common practice and motivation of all involved
personnel can be difficult. Also, other already running protocols
concerning painmanagementmight interferewith ERAS, leading to
reduced or delayed implementation.
The primary endpoint of this study was to evaluate the
adherence to the postoperative targets of the ERAS protocol after
PD in a tertiary teaching hospital in Ghent, Belgium, and to
describe the short-term surgical outcomes. The secondary end-
points were the 30-day readmission rate, reoperation rate and
mortality.2. Material and methods
2.1. Study population and study design
All data of patients who underwent a pancreaticoduodenectomy
between August 2016 and December 2019 were retrospectively
reviewed. All patients gave their consent at time of treatment. The
Informed consent was approved by the Ethical comity of University
Hospital Gent, Belgium on Jun 21, 2019 with EC number: EC/
2019e074/sds. This work is fully compliant with the STROCSS
criteria [11]. The study was registered in accordance with the




A total of 170 patients were operated of whom 154 were
enrolled in the ERAS protocol postoperatively. The decision to
exclude patients from the ERAS protocol wasmade by the operating
surgeon pre- or intraoperatively based on the patient's age,
comorbidities, and unexpected difficulties during surgery such as
soft pancreatic parenchyma or a high risk anastomosis due to a
small Wirsung duct diameter, being known risk factors for devel-
oping a pancreatic fistula.2.2. ERAS protocol
A standardized pancreaticoduodenectomy was performed in all
cases. The surgical approach was subcategorized as PD with
antrectomy, pylorus-preserving pancreaticoduodenectomy (PPPD),
both with or without vascular reconstruction. The gastrojejunal
anastomosis was performed in an antegrade fashion in all cases.
Two abdominal drains and a soft, flexible rubber (penrose) drain
were routinely used. The medial and penrose drain were located
anterior and posterior of the pancreaticojejunostomy (PJ) respec-
tively, and the lateral drain was located posteriorly of the bile duct
anastomosis. As per ERAS protocol (Table 1) the nasogastric tube
(NGT) was removed on POD3. The patient started drinking at
POD2, an oral liquid diet (yogurt, tea, and soup) was started on
POD3, followed by lightly digestible food on POD4, and resuming
regular diet on POD5. The epidural catheter was removed on
POD2, followed by the removal of the urinary catheter. If no signs
of bile were present, the lateral drain was removed on POD2. The
medial drain was removed on POD3 and the penrose drain was, in
the absence of a postoperative pancreatic fistula (POPF), mobilised
on POD3, monitored by the drain lipase level and drain output on
POD3. No precise definition was used to evaluate a pancreatic
fistula. High lipase level and suspicious aspect of the drain fluid
were criteria used to define POPF. It was the decision of the
operating surgeon to remove the medial drain and start the
mobilisation of the penrose drain based on these criteria. The
patients were all mobilised on POD1.9
2.3. Outcome variables
Our primary outcome was to evaluate the adherence to the
different targets of the ERAS protocol postoperatively, and to
describe short-term surgical outcomes, including the overall
pancreatic surgery specific morbidities. The secondary endpoints
were the 30-day readmission rate, reoperation rates and
mortality.2.4. Patient characteristics
Sex, BMI, age at time of pancreatic surgery, medical history
(cardiac, vascular, respiratory, endocrinologic, neurologic, psychi-
atric, orthopaedic, and urogenital comorbidities), preoperative
biliary stenting, and intraoperative factors (duration of surgery, use
of somatostatin) were variables chosen for analysis based on their
clinical relevance in regard to the pancreatic surgery. All patients
were planned for surgery after adequate preoperative optimisation
and were subcategorised following the American Society of Anes-
thesiology (ASA) classification in 1, 2 or 3.
The pathologic indication was grouped into pancreatic adeno-
carcinoma (e.g. pancreaticobiliary type, intestinal type), benign
(e.g. pancreatitis, intraductal papillary mucinous neoplasia, cys-
tadenoma), and non-adenocarcinoma malignancy (e.g. chol-
angiocarcinoma, neuroendocrine tumour [NET], sarcoma).
Neoadjuvant radiation and chemotherapy were aggregated into a
single variable if a patient received neoadjuvant therapy.
Postoperative morbidity was measured according to the
Clavien-Dindo Classification [12]. Morbidity was defined as any
postoperative non-surgical (systemic) or surgical (local) complica-
tion that occurred in the same admission or within 30 days of
surgery. Non-surgical complications included respiratory events
(e.g. pneumonia), cardiac events (e.g. atrial fibrillation), cerebro-
vascular events (e.g. delirium), or renal problems. Surgical com-
plications included pancreatic surgery specific complications and
general surgical complications (eg. surgical site infection (SSI),
intra-abdominal abscess, and chyle leakage). Pancreatic surgery
specific complications were defined according the International
Study Group on pancreatic Surgery (ISGPS) for postoperative
pancreatic fistula (POPF), post-pancreatectomy haemorrhage
(PPH), delayed gastric emptying (DGE), and biliary fistula [4]. The
POPFwere classified in grade A, B, and C. Grade Awas a biochemical
leak; Grade B and C were true POPF, when a prolonged presence of
drains or a radiological or surgical intervention was deemed
necessary [13]. The classification of DGE is based on the duration of
nasogastric intubation, the inability to consume solid food by
certain postoperative days, the presence of vomiting, and the usage
of prokinetic drugs [14]. Postoperative mortality was defined as
death within 30 days after surgery. Patients were discharged when
criteria for adequate pain control on oral analgesia, adequate solid
diet and sufficient mobilisation were met and no morbidity was
present at the time of discharge. Removal of the penrose drain was
not considered mandatory before discharge.2.5. Statistical analysis
A descriptive analysis was performed on the different targets of
the ERAS protocol, and on patientrelated factors i.e. age, BMI,
comorbidities, preoperative biliary stenting, neo-adjuvant therapy,
postoperative complications, and LOS. Statistical analysis was per-
formed using SPSS (version 25.0) software. Data were presented as
means (standard deviation) for continuous variables. Categorical









Day before surgery - Normal oral nutrition until midnight
- Clear fluids until 2 h before induction of
anaesthesia
- No preanaesthetic medication
Day of surgery - Preoperative antimicrobial prophylaxis
- Mid-thoracic epidural anaesthesia
- Short-acting IV anaesthetic agent
- Warm IV- fluids and upper and lower body
bear hugger
- Patient sent to recovery ward (ICU setting)
- Start antithrombotic prophylaxis
POD 1 patient sent to
surgical ward
- Patient mobilises in bed
- Continue portable epidural analgesia-
Antiemetic if necessary
POD 2 - 10 cm retraction of NGT
- Free drinking up to 1.5 L
- Remove epidural analgesia
- Remove urinary catheter
- Start NSAID's based on pain score
- Remove lateral drain
- Continue mobilisation
POD 3 - Remove NGT
- Start oral liquid diet
- Remove medial drain and start mobilisation
of the penrose drain regarding the drain
lipase level and output
- Continue analgesics based on pain score
- Continue mobilisation
POD 4 - Start lightly digestible food
- Continue analgesics based on pain score
- Continue mobilisation
POD 5-10 - Start regular diet
- Continue analgesics based on pain score
- Continue mobilisation
- Discharge from hospital
ICU, intensive care unit; NGT, nasogastric tube; NSAID, nonsteroidal anti-
inflammatory drugs; POD, postoperative day.
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3.1. Patients’ characteristics
Between August 2016 and December 2019, 201 patients pre-
sented for a pancreaticoduodenectomy (PD). Thirty-four of them
were inoperable (16.9%); in 21 patients the tumour was considered
locally advanced, and in 13 patients hepatic or peritoneal metas-
tasis were confirmed intraoperatively. Of those 34 patients, 3 pa-
tients received neoadjuvant treatment andwere still operated on in
the period of this study. A total of 170 patients underwent a PD
operation of whom 154 (90.6%) patients were enrolled in the ERAS
protocol (Fig. 1).
Therefore, the population for analysis included 154 patients (94
male; 60 female patients). The mean age of the study group was
65.0 þ- 10.5 years. The demographics, preoperative, operative and
pathologic data of the ERAS group, and the non-ERAS group are
stated in Table 2. In the ERAS group 50 patients (32.5%) had 3 or
more comorbidities, and 60 patients (39.0%) were classified as ASA
Class III. The ASA class is known as a risk factor for surgical com-
plications [13]. Preoperative biliary stenting was done in 38 pa-
tients (24.7%), and 14 patients (9.1%) received neoadjuvant therapy.
One hundred and twenty-seven patients (82.5%) underwent a py-
lorus preserving pancreaticoduodenectomy. In 11 patients (7.1%) a
vascular reconstruction was indicated. Somatostatin was used
intraoperatively, and continued postoperatively in 87 patients
(56.5%). Final pathological diagnosis showed pancreatic10adenocarcinoma in 113 patients (73.4%), non-adenocarcinoma
malignancy in 20 patients (13.0%), and benign pathology in 21
patients (13.6%).
3.2. Study outcomes
The primary endpoint was to evaluate the adherence to the
ERAS protocol postoperatively. The nine targets of the ERAS pro-
tocol selected for evaluation are listed in Fig. 2.
As per ERAS protocol, the NGT has to be removed on POD3, a
liquid diet started on POD3, lightly digestible food on POD4, and a
regular diet on POD5. Seventy-four patients (49.0%) had their NGT
removed on POD3 (mean POD 4.6 ± SD 3.3). Eighty-three patients
(54.3%) tolerated liquid diet on POD3, and 73 patients (48.0%)
tolerated lightly digestible food on POD4. We were able to start a
regular diet by the fifth postoperative day in 52 patients (34.9%)
(mean POD 8.0 ± SD 4.6). The NGT needed to be replaced in 11
patients (7.1%) of whom 3 patients were re-operated on with
replacement of the NGT in the operating theatre. Delayed gastric
emptying was diagnosed in 44 patients (28.6%); 26 patients had
ISGPS Grade A, 8 patients had a grade B and 10 had a grade C DGE.
In 26 patients (17.7%) the epidural analgesia was removed on
POD2 according to the ERAS protocol (mean POD 3.97 ± SD 1.77),
followed by the removal of the urinary catheter on POD2 in 22
patients (15.6%) (mean POD 4.4 ± SD 3.7). In 7 patients (4.6%) (6
male; 1 female patient) the urinary catheter needed to be replaced;
2 needed to be re-operated for other reasons; 2 had postoperative
haematuria, 1 was preoperatively diagnosed with benign prostatic
hyperplasia, and 2 had no previous urological history.
The lateral abdominal drain was removed in 81 patients (52.9%)
on POD2 (mean POD 3.2 ± SD 3.2) in line with the ERAS protocol. In
total 5 patients (3.3%) had a biliary leakage, of whom 4 of them had
a suspicious aspect of the drain fluid in the lateral drain on POD2.
Three of themwere re-operated immediately on POD2; in 1 patient
the diagnosis of bile leakage was initially unclear, and re-operation
was performed on POD4. In one patient the lateral drain was
removed on POD2 without signs of bile. Re-operation was per-
formed for a bleeding of the gastroduodenal artery and intra-
operative a dehiscence of the bile duct anastomosis was detected; a
T-tube drain was inserted.
According to the ERAS protocol, the medial drain has to be
removed on POD3 and the penrose drain between POD3 and 10. In
39 patients (26.2%) the medial drain was removed on POD3 (mean
POD 5.2 ± SD 3.1), and in 95 patients (61.7%) the penrose drain was
removed between POD 3 and 10. In total 19 patients (12.3%) were
discharged with penrose drain in place; 7 patients had lymphatic
leakage, 11 patients were diagnosed with a POPF grade B, and 4
patients with a POPF grade C as per ISGPS definition. Seventy pa-
tients (46.1%) were discharged between POD5 and 10. Overall, the
average LOS was 13.2 ± 6.6 days.
The adherence to the different targets of the ERAS protocol in
percentages is demonstrated in Fig. 2. In line with these results, the
number of targets every patient achieved was calculated going
from 0 to 9 targets maximum (Fig. 3). A correlation between the
number of targets achieved, and the LOS is demonstrated in Fig. 3.
In regard to the LOS, the ERAS group was divided in 2 groups; 70
patients had a LOS 10 days, and 82 patients a LOS >10 days. The
adherence to the different targets of the ERAS protocol was ana-
lysed for the group of patients with a LOS >10 days. The last ach-
ieved target in every patient in postoperative days, and therefore a
predictor for a LOS >10 days, was calculated. In Fig. 4 the number of
the last achieved targets was presented in percentages of patients
with a LOS >10 days.
The pancreatic surgery specific complications, the surgical
complications, and non-surgical complications are listed in Table 3.
Fig. 1. Flow chart patient selection.
Table 2





Patient characteristics Age at time PD 65.0 ± 10.52 66.4 ± 15.9
Sex, n (%) Male 94 (61.0) 7 (43.75)
Female 60 (39.0) 9 (56.3)
Clinical characteristics BMI kg/m2 24.1 ± 4.6 26.8 ± 3.4
Comorbidities, n (%) 0 42 (27.3) 5 (31.3)
1 29 (18.8) 2 (12.5)
2 33 (21.4) 3 (18.8)
3 33 (21.4) 4 (25.0)
4 17 (11.0) 2 (12.5)
ASA, n (%) I 18 (11.7) 1 (6.3)
II 76 (49.4) 9 (56.3)
III 60 (39.0) 6 (37.5)
Preoperative data Pathologic diagnosis, n (%) Malignant 132 (85.7) 13 (81.3)
Benign 22 (14.3) 3 (18.8)
Biliary stenting, n (%) 38 (24.7) 4 (25.0)
Neoadjuvant therapy, n (%) 14 (9.1) 1 (6.3)
Intraoperative data Operation procedure PD, n (%) 27 (17.5) 3 (18.8)
PPPD, n (%) 127 (82.5) 13 (81.3)
Vascular reconstruction, n (%) 11 (7.1) 0 (0)
OR time, min 434.6 ± 106.1 457.8 ± 89.6
Use of somatostatin, n (%) 87 (56.5) 13 (81.3)
Pathological results Malignant cases
(ERAS n ¼ 132, non-ERAS n ¼ 13)
R0 Resection, n (%) 93 (70.5) 13 (100)
Tumour diameter, cm 2.6 ± 1.1 2.2 ± 1.2
Anatomopathological result Pancreatic adenocarcinoma, n (%) 113 (73.4) 7 (43.8)
Benign, n (%) 21 (13.6) 3 (18.8)
Non-adenocarcinoma malignancy, n (%) 20 (13.0) 6 (37.5)
Continuous variables are expressed with means þ - standard deviations; ERAS, enhanced recovery after surgery; PD, Pancreaticoduodenectomy; PPPD, pylorus-preserving
pancreaticoduodenectomy; SD, standard deviation; BMI, Body Mass Index; ASA, American Society of Anesthesiologists physical status classification; OR, operating room.
A.-S. Hufkens, S. van Cleven, L. Abreu de Carvalho et al. International Journal of Surgery Open 28 (2021) 8e16The in-hospital mortality was 2 (1.2%) within 30 days of surgery.
One patient died due to PPH and multiple organ failure, and
another patient died due to respiratory failure. A third patient died
due to PPH on POD38 and was therefore not calculated in the in-
hospital mortality within 30 days of surgery.
Re-operation within one month of surgery occurred in 21 pa-
tients (12.4%) (of whom 16 patients in the ERAS group [10.4%] and 511in the non-ERAS group [31.3%]). The data are shown in Table 4. In
total 16 patients in the ERAS group were re-operated within one
month of surgery. In 12 patients the indication for surgery was
detected following the ERAS protocol; 4 patients on the other hand
re-admitted after discharge with a postoperative complication that
needed re-operation. Of those 4 patients one had an intra-
abdominal abscess and 3 patients presented with a PPH. Eighteen
Fig. 2. The relative adherence to the different targets of the ERAS protocol is listed per target. The different colours indicate the distribution of the target in postoperative days. Dark
green shows the percentage of patients who achieved the target on time. POD ¼ postoperative day.
A.-S. Hufkens, S. van Cleven, L. Abreu de Carvalho et al. International Journal of Surgery Open 28 (2021) 8e16patients (10.6%) (of whom 13 patients in the ERAS group and 5 in
the non-ERAS group) were re-admitted within one month of sur-
gery after discharge (Table 5).4. Discussion
Pancreaticoduodenectomy is one of the most complex abdom-
inal operations with high morbidity and mortality rates, even in
high-volume centres. Because of the major postoperative compli-
cations, surgeons often prefer a more conservative approach what
might lead to an increase in LOS. The perioperative ERAS pathway
has shown to be a safe and a worthy replacement for conventional
management [2,3,8], but implementation is not always easy. In this
study the primary endpoint was to evaluate the adherence to the
different targets of the ERAS protocol postoperatively and to
describe the short-term surgical outcome.
_underThe adherence to the targets was found to be rather low.
Only a limited amount of studies, evaluating the adherence to the
different targets in the ERAS protocol, can be found in literature. In
a single centre study of Mahendran et al. (2018), the ERAS protocol
was evaluated in 50 patients with an adherence to the different
targets ranging from 82% to 90% [15]. A recently published study of
Zhang et al. (2019) evaluated the implementation of the ERAS
protocol for 176 patients. The NGT was removed in 80.1% of theFig. 3. The number of targets a patient achieved going from the maximum (¼ 9 targets) to t
the number of targets achieved is indicated in colour.
12patients on POD2 and solid food was tolerated on POD4 in 59.7% of
the patients. The epidural catheter was removed within 36 h in
100% of the patients, followed by the removal of the urinary cath-
eter in 71.6% of the patients [16]. In a Japanese study of Takagi et al.
(2018) the adherence to the targets was evaluated for 74 patients.
They described a protocol compliance of 30% for all postoperative
targets [8].
The adherence to the different postoperative targets in our
analysis was lower in comparison to the study of Zhang et al. [16] or
Mahendran et al. [15]. A possible explanation might be the rela-
tively higher morbidity rates and reoperation rates reported in our
analysis. In the study of Mahendran, only 6% of the patients expe-
rienced DGE and no patients with PPH or POPF were described [15].
In the study of Zhang et al. more POPF grade B (16.0% vs 6.5%), more
DGE grade B (8.5% vs 5.2%), but less DGE grade C (5.1% vs 6.5%) and
less PPH (2.8% vs 5.8%) were reported, and less patients were re-
operated within 1 month of surgery (4.5% vs 10.4%). The differ-
ence in postoperative morbidity and reoperation rate might be
related to a higher preoperative ASA score of the patients reported
in this study in comparison to the study of Zhang et al. (38.96% vs
25%). The ASA score is a known risk factor for postoperative com-
plications [16]. If a patient develops a postoperative complication a
more individual postoperative course is followed maintaining the
NGT or drainage longer than planned according to the ERAShe minimum (¼ 0 targets) is plotted. The length of hospital stay (LOS) in correlation to
Fig. 4. The number of the last achieved targets of the ERAS protocol (in percentages) for the group of patients with a LOS >10 days.
Table 3
Postoperative morbidities.
ERAS protocol (N ¼ 154) Non-ERAS protocol (N ¼ 16)
Pancreatic surgery specific complications POPF Grade A, n (%) 20 (13.0) 4 (25.0)
Grade B, n (%) 10 (6.5) 1 (6.3)
Grade C, n (%) 4 (2.6) 0 (0)
PPH, n (%) 9 (5.8) 2 (12.5)
DGE A, n (%) 26 (16.9) 9 (56.3)
B, n (%) 8 (5.2) 2 (12.5)
C, n (%) 10 (6.5) 2 (12.5)
Biliary leakage, n (%) 5 (3.3) 2 (12.5)
Surgical complications SSI, n (%) 11 (7.1) 1 (6.3)
Intra-abdominal abcess, n (%) 9 (5.8) 5 (31.3)
Stenosis Bile duct anastomosis, n (%) 2 (1.3) 0 (0)
Chyle leakage, n (%) 7 (4.6) 2 (12.5)
Non-surgical complications Cardiac, n (%) 15 (9.7) 4 (25.0)
Respiratory, n (%) 14 (9.1) 0 (0)
Neurological, n (%) 15 (9.7) 3 (18.8)
Renal, n (%) 10 (6.5) 1 (6.3)
Diabetes de novo, n (%) 4 (2.6) 1 (6.3)
Complication grade, n (%) Clavien-Dindo Classification 0 71 (46.1) 1 (6.3)
I 16 (10.4) 1 (6.3)
II 49 (31.8) 9 (56.3)
III A 2 (1.3) 1 (6.3)
III B 10 (6.5) 4 (25.0)
IV A 2 (1.3) 0 (0)
IV B 1 (0.7) 0 (0)
V 3 (2.0) 0 (0)
Readmission < 30 days after PD, n (%) 13 (8.4) 5 (31.3)
Reoperation < 30 days after PD, n (%) 16 (10.4) 5 (31.3)
Mortality < 30 days after PD, n (%) 2 (1.3) 0 (0)
ERAS, enhanced recovery after surgery; POPF, postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage; DGE, delayed gastric emptying; SSI, surgical site
infection; PD, pancreaticoduodenectomy; BD anastomosis, bile duct anastomosis.
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postoperative targets might be the setting of a tertiary teaching
hospital with an important rotation of surgical trainees, fellows,
anaesthetic trainees, physiotherapist, and nurses, whomight not be
routinely informed about the ERAS protocol. The entire team must
work in an united way to achieve the targets of the ERAS protocol
on time. Fig. 2 illustrates that many targets are achieved with a 1 or
2 day delay. This implies that also for surgeons the protocol is rather
new, and surgeons still tend to be careful in regard to drain removal
and oral food intake. In order to improve the adherence to the13protocol, multidisciplinary staff meetings might be organised to
facilitate the communication and evaluate the different targets on a
daily basis.
Three drains are routinely placed in our department to evaluate
common pancreatic surgery related complications postoperatively.
In the ERAS group, 5 patients had biliary leakage, of whom 4 were
diagnosed early because of bile in the drain. In total, 10 grade B
POPF, 4 grade C POPF were reported, and 19 patients were dis-
charged with a penrose drain (12 POPF; 7 lymphatic leakage). In
literature the use of drainage is still controversial. In this study 4/5
Table 4
Re-operation within one month of surgery.
ERAS protocol Reason of re-operation Readmission Management Mortality <(30 days) LOS
1 Yes Hypovolemic shock (GDA) No Interventional radiology No 16
2 Yes 1) Intestinal leakage
2) Hypovolemic shock (CHA)
Yes 1) Surgery 2) Interventional radiology No 25
3 No Biliary leakage No Surgery No 37
4 Yes Biliary leakage No Surgery No 24
5 Yes Haemorrhage (GDA) No Interventional radiology þ Surgery Yes /
6 Yes Intestinal ischemia No Surgery x5 No 56
7 Yes Biliary leakage x2 Yes Surgery x2 No 20
8 No Biliary leakage No Surgery No 15
9 No Haemorrhage (GDA) Yes Interventional radiology No 20
10 Yes Haemorrhage (LGA) No Interventional radiology No 17
11 Yes 1) Stenosis BD anastomosis
2) hypovolemic shock (GDA)
Yes 1) Surgery 2) Interventional radiology No 20
12 Yes Intra abdominal abscess Yes Interventional radiology No 13
13 Yes Stenosis BD anastomosis No Surgery No 22
14 No Haemorrhage (PJ anastomosis) Yes Surgery þ interventional radiology No 14
15 No Incarcerated umbilical hernia No Surgery No 13
16 Yes Biliary leakage No Surgery No 14
17 Yes Haemorrhage (BD anastomosis) Yes Surgery No 8
18 Yes Hypovolemic shock (GDA) þ Biliary leakage No Surgery Yes Death POD 38
19 Yes Hypovolemic shock (PJ anastomosis) No Surgery No 19
20 Yes Biliary leakage No Surgery No 20
21 Yes Haemorrhage (GJ anastomosis) No Endoscopy No 17
ERAS, enhanced recovery after surgery; LOS, Length of hospital stay; GDA, gastroduodenal artery; CHA, common hepatic artery; LGA, left gastric artery; BD anastomosis, bile
duct anastomosis; PJ anastomosis, pancreaticojejunostomy anastomosis; POD, postoperative day: GJ anastomosis, gastrojejunal anastomosis.
Table 5
Readmission within one month of surgery after discharge.
ERAS protocol Date of discharge Reason of readmission Management
1 Yes 25 Hematemesis þ melena Interventional radiology (CHA)
2 Yes 20 Woundinfection Conservative
3 No 20 Hypovolemic shock Interventional radiology (GDA)
4 Yes 20 Hypovolemic shock Interventional radiology (GDA)
5 Yes 13 Intra-abdominal abscess Interventional radiology
6 Yes 17 Woundinfection Conservative
7 No 14 Hypovolemic shock Surgery þ interventional radiology
8 Yes 9 Diarrhea Conservative
9 Yes 8 Hypovolemic shock Surgery (BD anastomosis)
10 Yes 20 Change aspect drain fluid Conservative
11 Yes 9 Intra-abdominal collection (POPF B) Conservative
12 Yes 15 Fever of unknown origin Conservative
13 No 14 Vomiting Conservative
14 No 12 Intra-abdominal collection Conservative
15 No 12 Intra-abdominal collection Conservative
16 Yes 9 Anemia þ anorexia Blood transfusion
17 Yes 9 Anorexia TPN
18 Yes 12 Diarrhea þ anorexia TPN
ERAS, enhanced recovery after surgery; CHA, common hepatic artery; GDA, gastroduodenal artery; BD anastomosis, bile duct anastomosis; TPN, total parenteral nutrition.
A.-S. Hufkens, S. van Cleven, L. Abreu de Carvalho et al. International Journal of Surgery Open 28 (2021) 8e16patients (80%) with biliary leakage, and 13/14 patients (92,9%) with
POPF were detected immediately, thanks to the routine drain
placement. The present results are in line with a previous report of
Addison et al. where routine placement of drains is supported in
order to decrease serious morbidity. However the length of
drainage is associated with an increase of morbidity thus stimu-
lating an early drain removal policy [17]. Patients with drains have a
prolonged LOS, a higher incidence of DGE, and pancreatic fistula
[1,18,19]. In contrast, the 30-day mortality seems higher in the
group of patients without drains [19]. A prospective multi-centre
trial of Van Buren et al. was stopped early because mortality
increased from 3% to 12% in the group without intraperitoneal
drainage [20]. In this studymost of the postoperative complications
regarding POPF, chyle leakage or bile leakage were detected
following the ERAS protocol. Based on these results the inclusion of
all the patients in the ERAS protocol was preferred, even for pa-
tients at high risk for postoperative complications. In case of a
postoperative complication, the ERAS protocol was automatically
adapted with prolonged drainage or reoperation if necessary.14Delayed postpancreatectomy haemorrhage (>24 h postoperatively)
is not routinely monitored in the ERAS protocol and associatedwith
a high morbidity and mortality [21,22]. Nine patients of the ERAS
group presented with a hypovolemic shock caused by a delayed
bleeding postoperatively. Of these 9 patients, three were already
discharged. In the literature pancreatic fistulas are considered to
play a crucial role in the pathogenesis of PPH [21e23]. In this study
4/11 (36.4%) patients with a POPF developed a PPH. Patients with a
known POPF should be more closely monitored after discharge.
The secondary endpoints were the readmission rate, the reop-
eration rate, and mortality within 30 days of surgery. The read-
mission rate within 30 days of surgery for patients in the ERAS
group (8.4%) was lower than that reported in the study of Zhang
et al. (10.2%). In the study of Zhang et al., patients with a POPF grade
B or DGE grade B, or C weremore likely to be re-admitted within 30
days of surgery (P < 0.001) [16]. In this study the reasons for
readmission were more diverse; only 3/13 patients presented with
DGE, and 4/13 presented with a POPF grade B or C. In total 4/13
patients (30.8%) who re-admitted needed endovascular or surgical
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followed the ERAS protocol were discharged with a postoperative
complication not detected following the ERAS protocol. Lessing
et al. (2019) investigated the impact on morbidity, mortality, and
long-term survival after early re-operation following PD. The most
common indications for reoperation were anastomotic leaks, fol-
lowed by PPH, and wound complications [24]. In this study similar
results were found. The most common indication for re-operation
is PPH (11/21), followed by bile leakage (7/21). The mortality
within 30 days after reoperation is 4.8%. This is much lower than
themortality rate (18.7%) reported in the study of Lessing et al. [24].
In the literature LOS is often the primary endpoint to evaluate
the implementation of the ERAS protocol. In this study, the ERAS
protocol was evaluated according to the adherence to the different
targets. Interestingly, of the 62 patients who achieved 5 or more
targets still 31% had a LOS of more than 10 days. This implies that
the LOS is influenced by multiple factors, and is therefore not a
good parameter to evaluate the implementation of an ERAS pro-
tocol. Not only patient recovery, but also the healthcare system
contribute to the timing of discharge. Healthcare systems differ a
lot among countries. In Asian countries (e.g. Japanese, Korean,
Chinese) hospitals usually provide not only postoperative care,
but also subsequent rehabilitation [1,2,7,8]. On the contrary, in the
UK it is common practice to discharge patients from the hospital
early, and continue care in the community. Furthermore the
medical insurance differs between countries, contributing to a
higher heterogeneity regarding LOS [8]. The overall trend after
starting the ERAS protocol tends towards a shorter LOS
[1,7e10,15]. In this study a similar trend has been found regarding
LOS. The better the adherence to the ERAS protocol, the shorter
the LOS. In the study of Zhang et al., patients with a POPF grade B
or DGE grade B or C were significantly correlated with a longer LOS
(p < 0.001). The failure to remove the NGT on POD2 (p ¼ 0.036) or
tolerate liquid diet on POD3 (p ¼ 0.014) were predictors for a
longer LOS, and therefore considered ‘failure’ to the ERAS protocol
[16]. In our study the presence of a penrose drain and the inability
to tolerate solid food were 2 targets associated with a LOS >10
days. These results confirm that DGE and POPF are important
causes of a prolonged LOS as stated by others [9,16,25,26]. Despite
the fact that a postoperative pancreatic fistula was less frequently
present than DGE, as the presence of a postoperative pancreatic
fistula has been reported being the most important predictor of
DGE [26,27], DGE on itself is frequent in our population (28.6%)
and might be due to a very high percentage of pylorus preserving
pancreaticoduodenectomy (82.5%), but DGE has also been asso-
ciated with age  75 years old, male gender, or a prolonged
operating time [27]. In this study the mean LOS was 13.2 þ- 6.6
days, with a median of 11 days. This is shorter than observed in
most Japanese or Chinese high-volume hospitals, but much longer
than seen in the US.
This study had certain limitations. First of all this study has a
retrospective design. Therefore we could not control for whether
patients were in an ERAS or fast-track perioperative care protocol. It
was a decision made by the two main operating surgeons at the
hospital, but no clear definition was used to exclude patients.
Although the ISGPScriteria forPOPFwereevaluated inallpatients, the
decision to maintain the drains was surgeon-dependent. This limits
the external validity and applicability to compare results to other
healthcare centres.ThisstudyusedamodifiedERASprotocol thatwas
feasible to be implemented in the hospital setting, instead of using all
27 recommendations of the ERAS guidelines. In other centres,
modified ERAS protocols have been applied following the elements
that were practically possible. It is therefore difficult to compare the
adherence of the ERAS targets, especially regarding the postoperative
LOS, one of the most frequently chosen primary outcomes.155. Conclusion
Pancreaticoduodenectomy remains a complex surgical proced-
ure with significant morbidity. The ERAS protocol is a formalised
perioperative care approach that improves the postoperative
coursewithout compromising surgical outcome and leads to earlier
detection of postoperative complications. Only a limited amount of
studies, evaluating the adherence to the different targets in the
ERAS protocol, can be found in the literature. Considering the
adherence to the targets of the ERAS protocol, efficient imple-
mentation requires strict follow-up of all included ERAS elements,
but should not be restricted to low-risk patients. In this study most
complications were detected along the ERAS pathway, indicating
that also patients at high-risk for complications could be included
in the ERAS-group. Delayed gastric emptying and postoperative
pancreatic fistula are predictors for a prolonged LOS. Length of
hospital stay is influenced by multiple factors and therefore not a
good parameter to evaluate implementation of an ERAS protocol.
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